Seven winners have been selected for the third round of the Daedalus Fund for Innovation awards. This Weill Cornell Medicine program helps advance promising applied and translational research projects and emerging technologies with commercial potential. Thanks to donors and friends who have supported this critical initiative, the award recipients will each receive $100,000 to fund proof-of-concept studies that may help translate their discoveries into effective treatments for patients.
“The most challenging time for translational research is the period after initial discovery, in what is known as the ‘pre-competitive’ space, when investigators need to develop validation data in order to attract partners and investment from industry and/or the venture capital community,” says Larry Schlossman, managing director of BioPharma Alliances and Research Collaborations. “The Daedalus Fund is designed to bridge the ‘development
gap’ by providing philanthropic support at this critical juncture.”